Stronach Regional Cancer Centre, Newmarket, ON Canada.
J Appl Clin Med Phys. 2013 May 6;14(3):4269. doi: 10.1120/jacmp.v14i3.4269.
Recently, volumetric-modulated arc therapy (VMAT) has demonstrated the ability to deliver radiation dose precisely and accurately with a shorter delivery time compared to conventional intensity-modulated fixed-field treatment (IMRT). We applied the hypothesis of VMAT technique for the treatment of thoracic esophageal carcinoma to determine superior or equivalent conformal dose coverage for a large thoracic esophageal planning target volume (PTV) with superior or equivalent sparing of organs-at-risk (OARs) doses, and reduce delivery time and monitor units (MUs), in comparison with conventional fixed-field IMRT plans. We also analyzed and compared some other important metrics of treatment planning and treatment delivery for both IMRT and VMAT techniques. These metrics include: 1) the integral dose and the volume receiving intermediate dose levels between IMRT and VMATI plans; 2) the use of 4D CT to determine the internal motion margin; and 3) evaluating the dosimetry of every plan through patient-specific QA. These factors may impact the overall treatment plan quality and outcomes from the individual planning technique used. In this study, we also examined the significance of using two arcs vs. a single-arc VMAT technique for PTV coverage, OARs doses, monitor units and delivery time. Thirteen patients, stage T2-T3 N0-N1 (TNM AJCC 7th edn.), PTV volume median 395 cc (range 281-601 cc), median age 69 years (range 53 to 85), were treated from July 2010 to June 2011 with a four-field (n = 4) or five-field (n = 9) step-and-shoot IMRT technique using a 6 MV beam to a prescribed dose of 50 Gy in 20 to 25 F. These patients were retrospectively replanned using single arc (VMATI, 91 control points) and two arcs (VMATII, 182 control points). All treatment plans of the 13 study cases were evaluated using various dose-volume metrics. These included PTV D99, PTV D95, PTV V9547.5Gy(95%), PTV mean dose, Dmax, PTV dose conformity (Van't Riet conformation number (CN)), mean lung dose, lung V20 and V5, liver V30, and Dmax to the spinal canal prv3mm. Also examined were the total plan monitor units (MUs) and the beam delivery time. Equivalent target coverage was observed with both VMAT single and two-arc plans. The comparison of VMATI with fixed-field IMRT demonstrated equivalent target coverage; statistically no significant difference were found in PTV D99 (p = 0.47), PTV mean (p = 0.12), PTV D95 and PTV V9547.5Gy (95%) (p = 0.38). However, Dmax in VMATI plans was significantly lower compared to IMRT (p = 0.02). The Van't Riet dose conformation number (CN) was also statistically in favor of VMATI plans (p = 0.04). VMATI achieved lower lung V20 (p = 0.05), whereas lung V5 (p = 0.35) and mean lung dose (p = 0.62) were not significantly different. The other OARs, including spinal canal, liver, heart, and kidneys showed no statistically significant differences between the two techniques. Treatment time delivery for VMATI plans was reduced by up to 55% (p = 5.8E-10) and MUs reduced by up to 16% (p = 0.001). Integral dose was not statistically different between the two planning techniques (p = 0.99). There were no statistically significant differences found in dose distribution of the two VMAT techniques (VMATI vs. VMATII) Dose statistics for both VMAT techniques were: PTV D99 (p = 0.76), PTV D95 (p = 0.95), mean PTV dose (p = 0.78), conformation number (CN) (p = 0.26), and MUs (p = 0.1). However, the treatment delivery time for VMATII increased significantly by two-fold (p = 3.0E-11) compared to VMATI. VMAT-based treatment planning is safe and deliverable for patients with thoracic esophageal cancer with similar planning goals, when compared to standard IMRT. The key benefit for VMATI was the reduction in treatment delivery time and MUs, and improvement in dose conformality. In our study, we found no significant difference in VMATII over single-arc VMATI for PTV coverage or OARs doses. However, we observed significant increase in delivery time for VMATII compared to VMATI.
最近,容积调强弧形治疗(VMAT)与传统强度调制固定野治疗(IMRT)相比,能够更精确、更准确地传递辐射剂量,同时缩短治疗时间。我们将 VMAT 技术应用于胸段食管癌的治疗,旨在确定大胸段食管计划靶区(PTV)的优越或等效适形剂量覆盖,同时更好地保护危及器官(OARs)的剂量,并减少治疗时间和机器跳数(MU)。与传统的固定野 IMRT 计划相比,我们还分析和比较了这两种技术的其他一些重要治疗计划和治疗实施指标。这些指标包括:1)IMRT 和 VMAT 计划的积分剂量和中间剂量水平的体积;2)使用 4D CT 确定内部运动范围;3)通过患者特异性 QA 评估每个计划的剂量学。这些因素可能会影响整体治疗计划质量和个体治疗计划技术的治疗结果。在这项研究中,我们还研究了使用双弧和单弧 VMAT 技术对 PTV 覆盖、OARs 剂量、MU 和治疗时间的影响。13 例 T2-T3 N0-N1(AJCC 第 7 版 TNM)的患者,PTV 体积中位数为 395 cc(范围 281-601 cc),中位年龄 69 岁(范围 53-85),2010 年 7 月至 2011 年 6 月期间,使用 6 MV 射线进行四野(n=4)或五野(n=9)步进式 IMRT 技术治疗,每个野给予 50 Gy,20-25 次分割。这些患者采用单弧(VMATI,91 个控制点)和双弧(VMATII,182 个控制点)进行回顾性重新计划。使用各种剂量-体积指标评估了 13 例研究病例的所有治疗计划。这些指标包括 PTV D99、PTV D95、PTV V9547.5Gy(95%)、PTV 平均剂量、Dmax、PTV 剂量适形性(Van't Riet 适形性指数(CN))、平均肺剂量、肺 V20 和 V5、肝 V30 和脊髓 Dmax prv3mm。还评估了总计划 MU 和束流传输时间。两种 VMAT 单弧和双弧计划均观察到等效的靶区覆盖。VMATI 与固定野 IMRT 的比较显示出等效的靶区覆盖;PTV D99(p=0.47)、PTV 平均剂量(p=0.12)、PTV D95 和 PTV V9547.5Gy(95%)(p=0.38)没有统计学上的显著差异。然而,VMATI 计划的 Dmax 明显低于 IMRT(p=0.02)。Van't Riet 剂量适形性指数(CN)也具有统计学意义(p=0.04)。VMATI 可降低肺 V20(p=0.05),而肺 V5(p=0.35)和平均肺剂量(p=0.62)无统计学差异。其他 OARs,包括脊髓、肝脏、心脏和肾脏,两种技术之间没有统计学上的显著差异。VMATI 计划的治疗时间减少了 55%(p=5.8E-10),MU 减少了 16%(p=0.001)。积分剂量在两种计划技术之间没有统计学差异(p=0.99)。两种计划技术的剂量分布没有统计学差异(VMATI 与 VMATII)。两种 VMAT 技术的剂量统计数据为:PTV D99(p=0.76)、PTV D95(p=0.95)、平均 PTV 剂量(p=0.78)、适形性指数(CN)(p=0.26)和 MU(p=0.1)。然而,与 VMATI 相比,VMATII 的治疗输送时间显著增加了两倍(p=3.0E-11)。基于 VMAT 的治疗计划对于胸段食管癌患者是安全可行的,与标准的 IMRT 相比,具有相似的治疗目标。VMATI 的主要优势在于治疗输送时间和 MU 的减少,以及剂量适形性的改善。在我们的研究中,我们发现对于 PTV 覆盖或 OARs 剂量,VMATII 并没有明显优于单弧 VMATI。然而,我们观察到 VMATII 的治疗输送时间比 VMATI 显著增加。